PL3295941T3 - Sposób wytwarzania postaci a grapiprantu - Google Patents

Sposób wytwarzania postaci a grapiprantu

Info

Publication number
PL3295941T3
PL3295941T3 PL17193737T PL17193737T PL3295941T3 PL 3295941 T3 PL3295941 T3 PL 3295941T3 PL 17193737 T PL17193737 T PL 17193737T PL 17193737 T PL17193737 T PL 17193737T PL 3295941 T3 PL3295941 T3 PL 3295941T3
Authority
PL
Poland
Prior art keywords
grapiprant
preparing form
preparing
Prior art date
Application number
PL17193737T
Other languages
English (en)
Inventor
Tamara NEWBOLD
Melissa SMITH
Christopher SEEKAMP
Robert Wenslow
Xia LU
Original Assignee
Aratana Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aratana Therapeutics, Inc. filed Critical Aratana Therapeutics, Inc.
Publication of PL3295941T3 publication Critical patent/PL3295941T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
PL17193737T 2014-03-06 2015-03-05 Sposób wytwarzania postaci a grapiprantu PL3295941T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461949006P 2014-03-06 2014-03-06
US201461996961P 2014-07-30 2014-07-30
EP17193737.8A EP3295941B1 (en) 2014-03-06 2015-03-05 Process for preparing form a of grapiprant
EP15758500.1A EP3113773B1 (en) 2014-03-06 2015-03-05 Crystalline forms of grapiprant
PCT/US2015/019043 WO2015134797A1 (en) 2014-03-06 2015-03-05 Crystalline forms of grapiprant

Publications (1)

Publication Number Publication Date
PL3295941T3 true PL3295941T3 (pl) 2020-11-16

Family

ID=54016295

Family Applications (3)

Application Number Title Priority Date Filing Date
PL15758500T PL3113773T3 (pl) 2014-03-06 2015-03-05 Krystaliczne postaci grapiprantu
PL17193737T PL3295941T3 (pl) 2014-03-06 2015-03-05 Sposób wytwarzania postaci a grapiprantu
PL19156369.1T PL3511000T3 (pl) 2014-03-06 2015-03-05 Krystaliczne postaci x2 grapiprantu

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL15758500T PL3113773T3 (pl) 2014-03-06 2015-03-05 Krystaliczne postaci grapiprantu

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL19156369.1T PL3511000T3 (pl) 2014-03-06 2015-03-05 Krystaliczne postaci x2 grapiprantu

Country Status (16)

Country Link
US (1) US9265756B2 (pl)
EP (4) EP3511000B1 (pl)
JP (2) JP6535683B2 (pl)
KR (2) KR101771385B1 (pl)
CN (11) CN107759589A (pl)
AU (1) AU2015227064B2 (pl)
CA (10) CA2997694C (pl)
DK (3) DK3511000T3 (pl)
ES (3) ES2816057T3 (pl)
MX (1) MX367376B (pl)
NZ (3) NZ733234A (pl)
PL (3) PL3113773T3 (pl)
PT (3) PT3511000T (pl)
RU (1) RU2638931C1 (pl)
TW (1) TWI537270B (pl)
WO (1) WO2015134797A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015134792A1 (en) * 2014-03-06 2015-09-11 Aratana Therapeutics, Inc. Compositions of grapiprant and methods for using the same
CN112292128A (zh) 2018-04-16 2021-01-29 阿瑞斯医疗有限公司 Ep4抑制剂和其用途
WO2020014465A1 (en) * 2018-07-11 2020-01-16 Arrys Therapeutics, Inc. Polymorphic compounds and uses thereof
US11254675B2 (en) 2019-08-12 2022-02-22 Cadila Healthcare Limited Process for preparation of grapiprant
WO2021226162A1 (en) 2020-05-05 2021-11-11 Arrys Therapeutics, Inc. Ep4 antagonists and their use in the treatment of proliferative diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
EP1861400B1 (en) * 2005-03-11 2010-05-26 RaQualia Pharma Inc Crystal forms of an imidazole derivative
KR101368519B1 (ko) * 2005-05-23 2014-02-27 노파르티스 아게 결정형 및 기타 형태의 4-아미노-5-플루오로-3-［6-(4-메틸피페라진-1-일)-1ｈ-벤즈이미다졸-2-일］-1ｈ-퀴놀린-2-온 락트산염
EP2101751A1 (en) * 2006-12-15 2009-09-23 Glaxo Group Limited Benzamide derivatives as ep4 receptor agonists
WO2010019796A1 (en) 2008-08-14 2010-02-18 Chemietek, Llc Heterocyclic amide derivatives as ep4 receptor antagonists
BR112013029319A2 (pt) 2011-05-18 2017-01-31 Raqualia Pharma Inc forma polimorfa i de ácido 4-{[4-({[4-(2,2,2-trifluoroetoxi)-1,2-benzisoxazol-3-il]oxi}metil)piperidina-1-il]metil}-tetrahidro-2h-pirano-4 carboxílico, forma polimorfa ii de ácido 4-{[4-({[4-(2,2,2-trifluoroetoxi)-1,2-benzisoxazol-3-il]oxi}metil)piperidina-1-il]metil}-tetrahidro-2h-pirano-4 carboxílico, uso e processo, e método para tratar condições de doença mediadas por atividade receptora de 5-ht4

Also Published As

Publication number Publication date
KR101697914B1 (ko) 2017-01-18
EP3113773B1 (en) 2019-09-18
ES2919346T3 (es) 2022-07-26
NZ733234A (en) 2018-08-31
CA2997692A1 (en) 2015-09-11
EP3520790A1 (en) 2019-08-07
EP3511000A1 (en) 2019-07-17
MX2016011023A (es) 2016-11-28
EP3113773A4 (en) 2017-05-10
NZ733225A (en) 2018-03-23
KR101771385B1 (ko) 2017-08-24
US9265756B2 (en) 2016-02-23
PT3113773T (pt) 2019-11-12
DK3511000T3 (da) 2022-05-30
DK3295941T3 (da) 2020-08-24
WO2015134797A1 (en) 2015-09-11
KR20160106779A (ko) 2016-09-12
PT3295941T (pt) 2020-08-25
CA2997694C (en) 2021-04-06
CN107540671A (zh) 2018-01-05
PL3511000T3 (pl) 2022-08-22
DK3113773T3 (da) 2019-11-18
CA2997703A1 (en) 2015-09-11
AU2015227064B2 (en) 2017-05-11
US20150250774A1 (en) 2015-09-10
EP3113773A1 (en) 2017-01-11
AU2015227064A1 (en) 2016-10-27
CN107759590A (zh) 2018-03-06
EP3295941A1 (en) 2018-03-21
CA2997694A1 (en) 2015-09-11
JP6535683B2 (ja) 2019-06-26
JP2018065819A (ja) 2018-04-26
CN107759589A (zh) 2018-03-06
CN107501262A (zh) 2017-12-22
CA2997718A1 (en) 2015-09-11
PT3511000T (pt) 2022-05-25
CN107400132A (zh) 2017-11-28
KR20170008889A (ko) 2017-01-24
CN110256426A (zh) 2019-09-20
TW201538500A (zh) 2015-10-16
EP3295941B1 (en) 2020-07-22
CN107501263A (zh) 2017-12-22
ES2816057T3 (es) 2021-03-31
CA2997697A1 (en) 2015-09-11
NZ724923A (en) 2018-03-23
RU2638931C1 (ru) 2017-12-19
CA2941019A1 (en) 2015-09-11
CA3168877A1 (en) 2015-09-11
PL3113773T3 (pl) 2020-05-18
CA3105571A1 (en) 2015-09-11
CN107759591A (zh) 2018-03-06
TWI537270B (zh) 2016-06-11
CN105764508A (zh) 2016-07-13
CA2997741A1 (en) 2015-09-11
ES2755396T3 (es) 2020-04-22
JP2017507161A (ja) 2017-03-16
CN113087705A (zh) 2021-07-09
MX367376B (es) 2019-08-16
CA2997746A1 (en) 2015-09-11
EP3511000B1 (en) 2022-04-27
CN107573339A (zh) 2018-01-12

Similar Documents

Publication Publication Date Title
HRP20201847T1 (hr) Postupak za pripremu spoja diariltiohidantoina
HUE059158T2 (hu) Eljárás pridopidin elõállítására
SG11201704014WA (en) Process for preparing a polyetheramine
PT3129356T (pt) Processo para produção de enzalutamida
IL253877A0 (en) Process for preparing 3-chloro-2-vinylphenylsulfonates
IL252423A0 (en) Ajoan production process
PT3295941T (pt) Processo para preparar a forma a do grapiprant
SG11201704523WA (en) A process for the manufacture of idalopirdine
IL246244B (en) Process for making urea-sulphur fertilizer
IL243795A0 (en) A process for the preparation of a quinazoline derivative
EP3341169C0 (en) METHOD FOR FORMING A CERAMIC PRODUCT
IL255977B (en) A new process for the preparation of enzalutamide
IL249283A0 (en) Process for the preparation of 3-chloro-2-vinylphenol
IL252471A0 (en) A process for the production of idalopyridine
PL3209661T3 (pl) Sposób wytwarzania polimorfu rywaroksabanu
GB201409448D0 (en) A method of manufacture for a container
GB201407999D0 (en) A Method of manufacture for a container
GB201406774D0 (en) A method of manufacture for a container